NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

This trial is testing a dendritic cell vaccine — a type of personalized immune therapy made from the patient's own immune cells and trained to recognize ovarian cancer — given before the standard chemotherapy (neoadjuvant setting). The goal is to see whether priming the immune system early improves responses to treatment in advanced ovarian cancer. **You may be eligible if...** - You are a woman over 18 with confirmed primary epithelial ovarian cancer - Your cancer has spread extensively in the abdomen and cannot be operated on first (you need chemotherapy before surgery) - Your cancer is high-grade or low-grade serous type, stage IIIb or higher - You have a good performance status and adequate blood counts and organ function **You may NOT be eligible if...** - You have a different type of ovarian cancer (e.g., mucinous or clear cell) - You have other serious health conditions affecting immune function - You are not a candidate for eventual surgery after chemotherapy Talk to your doctor to see if this trial is right for you.